Anti-VEGF treatment for acute ROP – not yet recommended!

نویسنده

  • Clare Gilbert
چکیده

cities in lowand middle income countries. We don’t yet know how effective PRN treatment might be when retreatment is guided by visual acuity alone, as both visual acuity and retinal thickness were measured at each visit in these trials. Although intermittent regimes reduce the number of injections, patients still have to be reviewed every 1–2 months, which leads to very busy clinics; this is also a significant burden for the patients and for their families.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Antivascular endothelial growth factor in the treatment of retinopathy of prematurity.

PURPOSE OF REVIEW To review the most recent literature regarding the clinical experience of antivascular endothelial growth factor (anti-VEGF) therapies in the treatment of retinopathy of prematurity (ROP). RECENT FINDINGS Anti-VEGF agents in stage 3+ and aggressive posterior ROP have been shown to induce rapid ROP regression. However, significant reoccurrence rates can require repeat injecti...

متن کامل

Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy

Retinopathy of prematurity (ROP) remains a leading cause of childhood blindness, affecting infants born prematurely. ROP is characterized by the onset of delayed physiological retinal vascular development (PRVD) and followed by pathologic neovascularization into the vitreous instead of the retina, called intravitreal neovascularization (IVNV). Therefore, the therapeutic strategy for treating RO...

متن کامل

Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)

BACKGROUND Retinopathy of Prematurity (ROP) is one of the most common causes of childhood blindness worldwide. Comparisons of anti-VEGF and laser treatments in ROP are relatively lacking, and the data are scattered and limited. The objective of this meta-analysis is to compare the efficacy of both treatments in type-1 and threshold ROP. METHODS A comprehensive literature search on ROP treatme...

متن کامل

بررسی شاخص‌های فاکتور رشد آندوتلیال عروقی، لپتین و فاکتور رشد شبه انسولین در رتینوپاتی نارسی

Background & Aims: Retinopathy of prematurity (ROP) is one of the most causes of retinal detachment and blindness. Although many studies have been conducted on the pathophysiology of ROP, the exact mechanism is yet under investigation. This study aimed at evaluating the role of serum vascular endothelial growth factor (VEGF), insulin like growth factor-I (IGF-I), and its binding protein (IGFBP-...

متن کامل

Anti-vascular endothelial growth factor treatment for retinopathy of prematurity

Retinopathy of prematurity (ROP) is a proliferative disorder of the developing retina in premature and low birth weight infants. Recently, the role of vascular endothelial growth factor (VEGF) in the pathophysiology of ROP has been well studied and anti-VEGF drugs have been used in phase 2 to treat ROP patients in many ways. At first, ophthalmologists began to give intravitreal bevacizumab (IVB...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 27  شماره 

صفحات  -

تاریخ انتشار 2014